home / stock / tlppf / tlppf quote
Last: | $9.50 |
---|---|
Change Percent: | 2.04% |
Open: | $9.6 |
Close: | $9.50 |
High: | $9.6 |
Low: | $8.9 |
Volume: | 2,450 |
Last Trade Date Time: | 05/01/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$9.5 | $9.6 | $9.5 | $9.6 | $8.9 | 2,450 | 05-01-2024 |
$9.8 | $9.96 | $9.8 | $10 | $9.575 | 13,412 | 04-30-2024 |
$10 | $10.1 | $10 | $10.1 | $9.952 | 7,850 | 04-29-2024 |
$9.63 | $9.84 | $9.63 | $9.84 | $9.63 | 10,592 | 04-26-2024 |
$9.65 | $10.08 | $9.65 | $10.08 | $9.4 | 1,680 | 04-25-2024 |
$9.81 | $9.98 | $9.81 | $9.98 | $9.76 | 7,905 | 04-24-2024 |
$9.14 | $0 | $9.14 | $0 | $0 | 28,453 | 04-23-2024 |
$9.14 | $9.15 | $9.14 | $9.15 | $9.14 | 3,012 | 04-22-2024 |
$8.825 | $9.15 | $8.825 | $9.15 | $8.775 | 670 | 04-19-2024 |
$9.02 | $8.96 | $9.02 | $9.02 | $8.96 | 1,375 | 04-18-2024 |
$8.14 | $8.16 | $8.14 | $8.318 | $8.14 | 8,266 | 04-17-2024 |
$8.61 | $8.3 | $8.61 | $8.61 | $8.3 | 5,740 | 04-16-2024 |
$8.68 | $8.748 | $8.68 | $8.748 | $8.68 | 2,715 | 04-15-2024 |
$8.25 | $8.69 | $8.25 | $8.69 | $8.25 | 9,900 | 04-12-2024 |
$8.21 | $0 | $8.21 | $0 | $0 | 30 | 04-11-2024 |
$8.21 | $8.21 | $8.21 | $8.21 | $8.21 | 100 | 04-10-2024 |
$8.2 | $8.23 | $8.2 | $8.23 | $8.2 | 2,800 | 04-09-2024 |
$8.34 | $8.456 | $8.34 | $8.456 | $8.34 | 4,625 | 04-08-2024 |
$8.37 | $0 | $8.37 | $0 | $0 | 59 | 04-05-2024 |
$8.37 | $8.36 | $8.37 | $8.37 | $8.33 | 1,400 | 04-03-2024 |
News, Short Squeeze, Breakout and More Instantly...
Telix Pharmaceuticals Ltd Company Name:
TLPPF Stock Symbol:
OTCMKTS Market:
MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024). Summary: Q1 2024 financial performance The Company...
QSAM Biosciences (OTCQB: QSAM) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share, at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the company a...
FDA Fast Track designation granted for TLX101-CDx for glioma (brain cancer) imaging Collaboration agreement announced for joint development and commercialisation with UCSF PharmaLogic announced as commercial manufacturing and pharmacy distribution partner MELBOURNE, Au...